$CAI earnings report

Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance. AlphAI read Caris Life Sciences's Third Quarter 2026 filing as mixed. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readCAI · Third Quarter 2026 · ended September 30, 2026

Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

→Mixed quarter

Total revenue increased 27%, molecular profiling services revenue increased 27%, and clinical cases increased approximately 21%, but gross margin declined to 66% from 68%, operating expenses increased 42%, net income declined, and quarterly operating cash flow and free cash flow were negative.

Revenue
$275M
27% y/y
Molecular profiling services, three months ended September 30, 2026
$263M
27% y/y
Gross margin · GAAP
66%
EPS · GAAP
$0.05
Full year 2026 outlook
$1.04 to $1.05 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended September 30GAAP$275.4M–27%
Molecular profiling services revenue, three months ended September 30GAAP$262.7M–27%
Pharma research and development services revenue, three months ended September 30GAAP$12.65M––
Gross profit, three months ended September 30GAAP$182.3M––
Gross margin, three months ended September 30GAAP66%––
Cost of services - Molecular profiling services, three months ended September 30GAAP$89.17M––
Cost of services - Pharma research and development services, three months ended September 30GAAP$3.90M––
Operating expenses, three months ended September 30GAAP$163M–42%
Selling and marketing expense, three months ended September 30GAAP$59.85M––
General and administrative expense, three months ended September 30GAAP$69.28M––
Research and development expense, three months ended September 30GAAP$33.84M––
Income from operations, three months ended September 30GAAP$19.32M––
Net income, three months ended September 30GAAP$15.3M––
Net income per share attributable to common shareholders, basic, three months ended September 30GAAP$0.05––
Net income per share attributable to common shareholders, diluted, three months ended September 30GAAP$0.05––
Adjusted EBITDA, three months ended September 30non-GAAP$44.4M––
Free cash flow, three months ended September 30non-GAAP−$39.7M––
Total revenue, nine months ended September 30GAAP$755.2M––
Molecular profiling services revenue, nine months ended September 30GAAP$725.8M––
Pharma research and development services revenue, nine months ended September 30GAAP$29.48M––
Income from operations, nine months ended September 30GAAP$51.52M––
Net income (loss), nine months ended September 30GAAP$14.10M––
Net income (loss) per share attributable to common shareholders, basic, nine months ended September 30GAAP$0.05––
Net income (loss) per share attributable to common shareholders, diluted, nine months ended September 30GAAP$0.05––
Adjusted EBITDA, nine months ended September 30non-GAAP$126.3M––
Net cash provided by operating activities, nine months ended September 30GAAP$39.11M––
Free cash flow, nine months ended September 30non-GAAP−$10.78M––

Segments

SegmentRevenueq/qy/y
Molecular profiling services, three months ended September 30, 2026The increase was primarily driven by an increase in total clinical case volume and ASP improvements.$262.7M–27%
Pharma research and development services, three months ended September 30, 2026Not stated.$12.65M––

Full year 2026 outlook

  • Revenue$1.04 to $1.05 billion
  • NoteGrowth of 28% to 29% compared to full year 2025.
  • NoteClinical therapy selection volume growth of approximately 20% compared to full year 2025.

Capital returns

  • Share repurchase program of up to $100.0 million.
  • Approximately $72.1 million remains available for repurchase under the existing Board authorization.
  • Repurchase of common stock of $31,371 thousand for the nine months ended September 30, 2026.

What drove it

  • Approximately 61,500 clinical cases, an increase of approximately 21% over the corresponding prior year period.
  • Over 358,000 total oncology tests.
  • Molecular profiling services revenue growth was primarily driven by higher total clinical case volume and ASP improvements.
  • Caris launched Caris Assure Therapy Response Monitoring and enhanced Caris Assure for Therapy selection.
  • Caris Confirm, a Whole Genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.

Concerns

  • Gross margin was 66%, compared to 68% in the corresponding prior-year period.
  • Operating expenses increased 42%, primarily due to headcount-related costs, increased research and development investment, and marketing expenditures.
  • Net income was $15.3 million, compared to $24.3 million in the corresponding prior-year period.
  • Net cash used in operating activities was $22.2 million, compared to net cash provided by operating activities of $62.4 million in the corresponding prior-year period.
  • The operating cash flow decrease was driven by commercial expansion and marketing expenditures, inventory build-up for new solution launches, and research and development efforts.
  • Free cash flow was $(39.7) million.

What to watch

  • Execution against full-year 2026 revenue guidance of $1.04 to $1.05 billion.
  • Clinical therapy selection volume growth of approximately 20% compared to full year 2025.
  • The planned launch of Caris Confirm before year-end.
  • Whether case-volume growth and ASP improvements continue to support molecular profiling services revenue.
  • Gross-margin performance, operating-expense growth, and cash usage associated with commercial expansion, marketing, inventory, and research and development.

Balance sheet and cash flow

  • Cash, cash equivalents, and restricted cash: $665,321 thousand as of September 30, 2026, compared to $797,799 thousand as of December 31, 2025.
  • Short-term marketable securities: $102,059 thousand as of September 30, 2026, compared to $2,295 thousand as of December 31, 2025.
  • Long-term indebtedness, net: $393,178 thousand as of September 30, 2026, compared to $378,823 thousand as of December 31, 2025.
  • Total liabilities: $616,142 thousand as of September 30, 2026, compared to $548,356 thousand as of December 31, 2025.
  • Accounts receivable: $133,322 thousand as of September 30, 2026, compared to $112,140 thousand as of December 31, 2025.
  • Supplies: $138,372 thousand as of September 30, 2026, compared to $63,625 thousand as of December 31, 2025.
  • Capitalized software and purchases of property and equipment: $49,887 thousand for the nine months ended September 30, 2026, compared to $11,170 thousand for the nine months ended September 30, 2025.
  • Net cash used in investing activities: $(150,004) thousand for the nine months ended September 30, 2026, compared to $(11,170) thousand for the nine months ended September 30, 2025.
  • Net cash used in financing activities: $(21,845) thousand for the nine months ended September 30, 2026, compared to net cash provided by financing activities of $661,590 thousand for the nine months ended September 30, 2025.

Analysis

Caris reported third-quarter revenue of $275.4 million, up 27% from $216.8 million. Molecular profiling services generated $262.7 million, also up 27%, and management attributed the increase to higher clinical case volume and ASP improvements. The company completed approximately 61,500 clinical cases, up approximately 21%, and reported over 358,000 total oncology tests. Molecular profiling remained the principal source of revenue, while pharma research and development services revenue was $12,651 thousand.

Gross profit was $182.3 million and gross margin was 66%, versus $147.5 million and 68% in the corresponding prior-year period. The two-point gross-margin decline occurred alongside revenue growth. Operating expenses rose 42% to $163.0 million, with the company citing headcount-related costs, higher research and development investment, and marketing expenditures. Income from operations was $19,316 thousand, compared with $32,642 thousand in the prior-year quarter.

Net income was $15.3 million, compared with $24.3 million, and basic and diluted net income per share were each $0.05, compared with $0.09 and $0.08, respectively. Adjusted EBITDA was positive at $44.4 million, but below $51.2 million in the corresponding prior-year period. For the first nine months, total revenue was $755,243 thousand, income from operations was $51,524 thousand, net income was $14,103 thousand, and Adjusted EBITDA was $126,322 thousand.

Cash conversion weakened in the quarter. Net cash used in operating activities was $22.2 million, compared with net cash provided by operating activities of $62.4 million in the prior-year quarter, while free cash flow was $(39.7) million compared with $55.3 million. Management attributed the operating-cash-flow decrease to commercial expansion and marketing, inventory build-up for new launches, and research and development. For the nine months, operating cash flow remained positive at $39,107 thousand, but free cash flow was $(10,780) thousand following $49,887 thousand of capitalized software and property and equipment purchases.

Caris increased its full-year 2026 revenue outlook to $1.04 to $1.05 billion, representing growth of 28% to 29%, and reaffirmed expected clinical therapy selection volume growth of approximately 20%. The balance sheet reported $665,321 thousand of cash, cash equivalents, and restricted cash, $102,059 thousand of short-term marketable securities, and $393,178 thousand of long-term indebtedness, net. The company also had approximately $72.1 million remaining under its $100.0 million share repurchase authorization.

Management, verbatim

This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year.

David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences

Caris Assure® is now available for therapeutic response monitoring, and Caris Confirm, our Whole Genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.

David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences

Not in the filing

stated, not guessed
  • Previous-release outlook was not provided, so no comparison of actual results with prior guidance is available.
  • Prior-quarter revenue, margins, earnings, cash flow, and segment comparisons were not reported.
  • Forward guidance for gross margin, operating expenses, tax rate, earnings, Adjusted EBITDA, operating cash flow, free cash flow, capital expenditures, cash, debt, or repurchases was not reported.
  • A quarterly dividend was not reported.
  • A specific driver for pharma research and development services revenue was not reported.
  • Year-over-year percentage changes for gross profit, gross margin, individual operating-expense categories, operating income, net income, EPS, Adjusted EBITDA, and nine-month results were not reported on their respective rows.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readCAI · Second Quarter 2026 · ended June 30, 2026

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

✓Strong quarter

Total revenue increased 45%, gross margin improved to 68%, net loss narrowed to $0.6 million, operating cash flow and free cash flow were positive, and the company raised full-year 2026 revenue guidance.

Revenue
$264M
45% y/y
Molecular profiling services
$252M
55% y/y
Gross margin · GAAP
68%
an approximate 500 bps improvement y/y
EPS · GAAP
$0.00
full year 2026 outlook
$1.03 billion to $1.04 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueGAAP$263.7M–45%
Molecular profiling services revenueGAAP$252.3M–55%
Gross profitGAAP$179.6M––
Gross marginGAAP68%–an approximate 500 bps improvement
Operating expensesGAAP$152.7M–16%
Net lossGAAP$600K––
Net loss per share attributable to common shareholders, basic and dilutedGAAP$0.00––
Adjusted EBITDAnon-GAAP$55.7M––
Net cash provided by operating activitiesGAAP$28.5M–a 291% improvement
Free cash flownon-GAAP$6.4M––
Clinical casesotherapproximately 59,200 clinical casesmore than 12%approximately 18%
MI Profile casesotherapproximately 48,300 MI Profile cases––
Caris Assure casesotherapproximately 10,700 Caris Assure cases––
Whole exome/whole transcriptome testsotherover 114,000 whole exome/whole transcriptome tests––
Total oncology testsotherover 345,000 total oncology tests––
Total profiles through June 30, 2026other1,130,000 total profiles––
Total matched profiles through June 30, 2026other845,000 total matched profiles––
Whole transcriptome profiles through June 30, 2026other783,000 whole transcriptome––
Whole exome profiles through June 30, 2026other733,000 whole exome profiles––

Segments

SegmentRevenueq/qy/y
Molecular profiling servicesThe increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements.$252.3M–55%

full year 2026 outlook

  • Revenue$1.03 billion to $1.04 billion
  • Notegrowth of 27% to 28% compared to full year 2025
  • Noteclinical therapy selection volume growth of approximately 20% compared to full year 2025

Capital returns

  • Announced a share repurchase program of up to $100 million, of which approximately $82.1 million remains available for repurchase under the existing Board authorization.

What drove it

  • Total revenue growth was driven primarily by 55% growth in molecular profiling services revenue.
  • Molecular profiling services revenue growth was primarily driven by an increase in total clinical case volume and ASP improvements.
  • The improvement in net cash provided by operating activities was driven by improved total clinical case volume and ASP improvements.
  • Operating expense growth was primarily driven by headcount-related costs.
  • The company launched Caris Detect, a multi-cancer early detection blood test.
  • The company launched Caris ChromoSeq and received MolDX approval for the whole genome tumor profiling assay for myeloid malignancies.
  • The company launched Caris MI Clarity, a next-generation prognostic tool for specified early-stage breast cancer patients.

Concerns

  • Caris reported a net loss of $0.6 million for the three months ended June 30, 2026.
  • Operating expenses increased 16% to $152.7 million, primarily driven by headcount-related costs.
  • The filing identifies risks related to commercialization and market acceptance of Caris Detect, payer reimbursement and coverage decisions, competition, regulatory requirements, indebtedness, data security, patient privacy, and reliance on third-party suppliers.

What to watch

  • Execution against full-year 2026 revenue guidance of $1.03 billion to $1.04 billion.
  • Clinical therapy selection volume growth of approximately 20% compared to full year 2025.
  • Sustained clinical case-volume growth and ASP improvements in molecular profiling services.
  • Commercialization, market acceptance, and payer reimbursement developments for Caris Detect, Caris ChromoSeq, and Caris MI Clarity.
  • Use of the remaining approximately $82.1 million available under the existing Board repurchase authorization.

Balance sheet and cash flow

  • Net cash provided by operating activities was $28.5 million for the three months ended June 30, 2026, as compared to net cash provided by operating activities of $7.3 million for the three months ended June 30, 2025, a 291% improvement.
  • Reported positive free cash flow of $6.4 million.

Analysis

Caris reported a strong second quarter, with total revenue of $263.7 million, up 45% from $181.4 million in the corresponding prior-year period. Molecular profiling services revenue was $252.3 million and increased 55%, making this service line the stated primary driver of company revenue growth. Management attributed the molecular profiling increase to higher total clinical case volume and ASP improvements.

Clinical activity supported the revenue result. The company completed approximately 59,200 clinical cases, an increase of approximately 18% over the corresponding prior-year period and more than 12% sequentially. The reported mix included approximately 48,300 MI Profile cases and approximately 10,700 Caris Assure cases. The company also reported over 114,000 whole exome/whole transcriptome tests and over 345,000 total oncology tests.

Margins and profitability improved substantially. Gross profit was $179.6 million and gross margin was 68%, compared with gross profit of $113.7 million and gross margin of 63% in the prior-year period. Operating expenses increased 16% to $152.7 million, primarily reflecting headcount-related costs, but grew materially slower than total revenue. Net loss narrowed to $0.6 million from $71.8 million, while Adjusted EBITDA was positive at $55.7 million.

Cash generation was also positive. Net cash provided by operating activities was $28.5 million, compared with $7.3 million in the prior-year period, a 291% improvement that the company attributed to improved clinical case volume and ASP improvements. Free cash flow was positive at $6.4 million. Caris also announced a repurchase program of up to $100 million, with approximately $82.1 million remaining available under the existing Board authorization.

For full-year 2026, Caris increased revenue guidance to $1.03 billion to $1.04 billion, representing growth of 27% to 28% compared to full year 2025. It reaffirmed clinical therapy selection volume growth of approximately 20% compared to full year 2025. Key execution items are continued volume and ASP progress in molecular profiling services, expense growth associated with headcount, and commercial adoption, reimbursement, and regulatory progress for newly launched products including Caris Detect, Caris ChromoSeq, and Caris MI Clarity.

Management, verbatim

This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine.

David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences

Our comprehensive approach gives every case real molecular depth, across more than 1.13 million patients with AI trained on it, that depth is what powers Caris Detect.

David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences

Not in the filing

stated, not guessed
  • GAAP operating income or loss
  • Prior-year Adjusted EBITDA
  • Prior-year free cash flow
  • Prior-quarter revenue, molecular profiling services revenue, gross profit, gross margin, operating expenses, net loss, net loss per share, Adjusted EBITDA, operating cash flow, and free cash flow
  • Gross profit percentage change
  • Operating income or loss guidance
  • Gross margin guidance
  • Operating expense guidance
  • Tax-rate guidance
  • Cash balance
  • Debt balance
  • Dividend information
  • Prior outlook needed to compare actual results with prior guidance

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about CAI earnings dates

When is Caris Life Sciences's next earnings date?
AlphAI has no date for CAI yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.